STAA STAAR SURGICAL CO
Ophthalmic Goods · Nasdaq · SEC CIK 718937 · Fiscal year ends 01/02
Financial factors as of 2026-10-02 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY42.4%
TTM net income YoY100.5%
TTM EPS YoY100.5%
Revenue 3-yr CAGR1.9%
Net income 3-yr CAGR-69.9%
Margins
Gross margin73.6%
Operating margin0.2%
Net margin0.2%
FCF margin5.4%
EBITDA margin2.9%
Returns
ROE0.1%
ROA0.1%
ROIC (approx.)0.2%
Asset turnover0.70x
Leverage & solvency
Liabilities / assets22.5%
Debt / equity0.00x
Current ratio4.68x
Interest coverage—
Cash quality & payout
Operating cash flow / net income40.37x
Accruals ratio-4.4%
Payout ratio—
Capex / revenue1.1%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-10-02 | 2026Q22026-07-03 | 2026Q12026-04-03 | 2025Q4*2026-01-02 | 2025Q32025-09-26 | 2025Q22025-06-27 | 2025Q12025-03-28 | 2024Q4*2024-12-27 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | $83.41M | $93.53M | $93.52M | $57.80M | $94.73M | $44.32M | $42.59M | $48.95M |
| Cost of revenue | $24.28M | $23.81M | $24.66M | $14.06M | $16.86M | $11.52M | $14.58M | $17.30M |
| Gross profit | $59.13M | $69.73M | $68.86M | $43.74M | $77.88M | $32.80M | $28.00M | $31.65M |
| R&D expense | $10.46M | $9.94M | $9.93M | $9.24M | $9.21M | $10.26M | $11.34M | $9.77M |
| SG&A expense | $53.68M | $59.63M | $60.88M | $66.58M | $59.38M | $62.76M | $85.41M | $59.56M |
| Operating income | $5.46M | $10.10M | $7.98M | -$22.84M | $18.49M | -$29.96M | -$57.40M | -$27.91M |
| Pretax income | $6.98M | $11.02M | $8.22M | -$20.65M | $18.79M | -$25.91M | -$54.49M | -$30.33M |
| Income tax | $1.41M | $2.97M | $3.01M | -$2.34M | $9.91M | -$9.10M | -$275,000 | $3.89M |
| Net income | $5.58M | $8.06M | $5.21M | -$18.31M | $8.88M | -$16.81M | -$54.21M | -$34.23M |
| EBITDA | $7.89M | $12.49M | $10.09M | -$20.83M | $20.49M | -$27.99M | -$55.06M | -$25.54M |
| EPS (basic) | 0.11 | 0.16 | 0.10 | — | 0.18 | -0.34 | -1.10 | — |
| EPS (diluted) | 0.11 | 0.16 | 0.10 | — | 0.18 | -0.34 | -1.10 | — |
| Weighted avg. shares (diluted) | 51.45M | 51.50M | 50.90M | — | 50.55M | 49.52M | 49.34M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $133.61M | $148.58M | $131.86M | $153.15M | $176.16M | $167.13M | $173.11M | $144.16M |
| Short-term investments | $72.80M | $32.91M | $32.02M | $34.39M | $16.50M | $22.75M | $49.65M | $86.33M |
| Receivables | $86.53M | $98.47M | $81.17M | $50.06M | $60.10M | $34.44M | $39.95M | $77.90M |
| Inventory | $48.58M | $49.53M | $52.66M | $58.42M | $55.09M | $55.16M | $50.50M | $44.58M |
| Current assets | $353.43M | $342.35M | $312.40M | $311.55M | $321.21M | $292.79M | $326.50M | $367.94M |
| PP&E, net | $68.53M | $69.93M | $71.74M | $73.32M | $72.61M | $74.42M | $74.96M | $84.89M |
| Goodwill | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M | $1.79M |
| Total assets | $485.16M | $475.20M | $451.12M | $451.68M | $456.36M | $437.78M | $457.36M | $509.52M |
| Current liabilities | $75.54M | $73.39M | $60.99M | $68.50M | $61.64M | $59.23M | $68.36M | $70.31M |
| Total liabilities | $109.03M | $109.81M | $98.75M | $107.49M | $102.58M | $101.21M | $107.39M | $112.19M |
| Shareholders' equity | $376.13M | $365.40M | $352.37M | $344.18M | $353.78M | $336.57M | $349.97M | $397.33M |
| Shares outstanding | 50.20M | 50.12M | 49.78M | 49.40M | 49.73M | 49.55M | 49.52M | 49.29M |
| Cash flow statement | ||||||||
| Operating cash flow | $27.32M | $19.69M | -$21.70M | -$3.91M | $2.67M | -$27.25M | -$5.73M | $642,000 |
| Capital expenditure | $935,000 | $494,000 | $443,000 | $1.68M | $883,000 | $1.79M | $1.47M | $5.72M |
| Free cash flow | $26.38M | $19.20M | -$22.14M | -$5.59M | $1.78M | -$29.04M | -$7.20M | -$5.08M |
| Investing cash flow | -$40.67M | -$1.37M | $2.15M | -$19.41M | $5.28M | $25.12M | $35.35M | -$19.50M |
| Financing cash flow | -$1.32M | -$1.50M | -$1.69M | -$50,000 | $983,000 | -$4.54M | -$948,000 | -$110,000 |
| Depreciation & amortization | $2.43M | $2.39M | $2.11M | $2.01M | $2.00M | $1.98M | $2.34M | $2.38M |
| Stock-based compensation | $5.52M | $6.56M | $4.82M | $8.61M | $8.16M | $7.80M | $6.01M | $4.67M |
| Share buybacks | — | — | — | $0 | $1.98M | — | — | — |
Free plan shows the latest 8 periods; Pro shows all 74 🔒
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.